share_log

Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62

Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62

花旗集團以買入評級啓動對Xenon Pharmicals的報道,宣佈目標股價爲62美元
Benzinga ·  01/04 04:47

Citigroup analyst David Hoang initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $62.

花旗集團分析師大衛·霍恩開始對Xenon Pharmicals(納斯達克股票代碼:XENE)進行報道,評級爲買入,並宣佈目標股價爲62美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論